News

R-Pharm Group announces positive results of CREDO 2, a pivotal global (1648 patients in 18 countries) Phase III clinical study of IL-6...
read more...
July 2
R-Pharm Holding, LLC (Headquarters: Moscow, Russia; Chairman: Alexey Repik, hereinafter R-Pharm) and Canon Medical Systems Corporation...
read more...
June 22
R-Pharm Group of Companies successfully registered Artlegia (olokizumab), a novel drug for treatment of rheumatoid arthritis in the first...
read more...
May 29
R-Pharm JSC has obtained official permission to conduct clinical trial in Russia to evaluate the efficacy and safety of radotinib for...
read more...
May 28
Deltyba® (delamanid) —an essential medicine according to the World Health Organization [1]—is now available in Russia for...
read more...
May 25
March 30, 2019 – R-Pharm Group has filed its first international patent application regarding biotech medicine that binds viral particles...
read more...
March 30
Considering COVID-19 pandemic, R-Pharm Group has taken the following measures to achieve better health protection of R-Pharm employees and...
read more...
March 24